First Time Loading...

NGM Biopharmaceuticals Inc
NASDAQ:NGM

Watchlist Manager
NGM Biopharmaceuticals Inc Logo
NGM Biopharmaceuticals Inc
NASDAQ:NGM
Watchlist
Price: 1.54 USD Market Closed
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

NGM Price Targets Summary
NGM Biopharmaceuticals Inc

Wall Street analysts forecast NGM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NGM is 1.7 USD with a low forecast of 1.57 USD and a high forecast of 2.1 USD.

NGM Lowest Forecast
Wall Street Target
1.57 USD
2% Upside
NGM Average Forecast
Wall Street Target
1.7 USD
10% Upside
NGM Highest Forecast
Wall Street Target
2.1 USD
36% Upside
Lowest
Price Target
1.57 USD
2% Upside
Average
Price Target
1.7 USD
10% Upside
Highest
Price Target
2.1 USD
36% Upside
NGM Biopharmaceuticals Inc Competitors:
Price Targets
S
002294
Shenzhen Salubris Pharmaceuticals Co Ltd
18% Upside
H
300086
Honz Pharmaceutical Co Ltd
393% Upside
93M1
MPH Health Care AG
100% Upside
LQDA
Liquidia Corp
101% Upside
S
002294
Shenzhen Salubris Pharmaceuticals Co Ltd
18% Upside
H
300086
Honz Pharmaceutical Co Ltd
393% Upside
93M1
MPH Health Care AG
100% Upside
LQDA
Liquidia Corp
101% Upside
2186
Luye Pharma Group Ltd
2% Upside
PFIZER
Pfizer Ltd
10% Upside
002001
Zhejiang Nhu Co Ltd
9% Upside
950
Lee's Pharmaceutical Holdings Ltd
14% Downside

Revenue
Forecast

Revenue Estimate
NGM Biopharmaceuticals Inc

For the last 6 years the compound annual growth rate for NGM Biopharmaceuticals Inc's revenue is -38%. The projected CAGR for the next 3 years is 101%.

-38%
Past Growth
101%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
NGM Biopharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
NGM Biopharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

See Also

Summary
NGM intrinsic value, competitors valuation, and company profile.
DCF Valuation
NGM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NGM stock valuation using valuation multiples.
Wall Street Estimates
NGM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NGM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NGM's stock price target?
Price Target
1.7 USD

According to Wall Street analysts, the average 1-year price target for NGM is 1.7 USD with a low forecast of 1.57 USD and a high forecast of 2.1 USD.

What is NGM Biopharmaceuticals Inc's Revenue forecast?
Projected CAGR
101%

For the last 6 years the compound annual growth rate for NGM Biopharmaceuticals Inc's revenue is -38%. The projected CAGR for the next 3 years is 101%.

ALPHA SPREAD
Join more than 134,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.